Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel:	Blood
Personen und Körperschaften:	Milanovic, Maja, Dörr, Jan, Lenze, Dido, Hummel, Michael, Dörken, Bernd, Schmitt, Clemens
In:	Blood, 116, 2010, 21, S. 2836-2836
Format:	E-Article
Sprache:	Englisch
veröffentlicht:	American Society of Hematology
Schlagwörter:	Cell Biology Hematology Immunology Biochemistry

author_facet	Milanovic, Maja Dörr, Jan Lenze, Dido Hummel, Michael Dörken, Bernd Schmitt, Clemens Milanovic, Maja Dörr, Jan Lenze, Dido Hummel, Michael Dörken, Bernd Schmitt, Clemens
author	Milanovic, Maja Dörr, Jan Lenze, Dido Hummel, Michael Dörken, Bernd Schmitt, Clemens
spellingShingle	Milanovic, Maja Dörr, Jan Lenze, Dido Hummel, Michael Dörken, Bernd Schmitt, Clemens Blood Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics. Cell Biology Hematology Immunology Biochemistry
author_sort	milanovic, maja
spelling	Milanovic, Maja Dörr, Jan Lenze, Dido Hummel, Michael Dörken, Bernd Schmitt, Clemens 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v116.21.2836.2836 <jats:title>Abstract</jats:title> <jats:p>Abstract 2836</jats:p> <jats:p>Premature senescence is a stress-inducible terminal cell-cycle arrest, which, like apoptosis, prevents propagation of aberrantly proliferating cells. DNA-damaging chemotherapy induces cellular senescence, particularly in cells where apoptosis is no longer available (e.g. due to Bcl2 over-expression). Since senescent cells remain vital, it is critical to understand their long-term fate and ultimate impact on outcome. Given the potential reversibility of senescence by additional genetic events, assessment of a senescence-associated tumorigenic capability appears to be crucial for the development of safe pro-senescent treatment regimens. Since “stemness” is a property that – either confined to a putative cancer stem cell population or endowed in all neoplastic cells – enables malignant transformation and propagation, we decided to investigate features of stemness in senescent Eμ-myc-transgenic B-cell lymphomas.</jats:p> <jats:p>Here, we compared expression changes of stem-cell related gene sets in proliferating vs. treatment-induced senescent (TIS) Eμ-myc lymphoma cells. The clonogenicity and proliferation capacity were assessed in cells released from TIS by acute inactivation of downstream senescence gatekeeper proteins, such as Suv39h1, Klf4 or p53.</jats:p> <jats:p>Our data show that embryonic stem cell-like (ESCL) gene expression signatures, associated with aggressive tumor behavior decrease with TIS induction in Eμ-myc lymphoma cells. However, the adult tissue stem cell (ATSC) gene signature is highly up-regulated, providing the senescent lymphoma cells with an alternative stemness-maintaining prospective. Similar conversion from an ESCL- to an ATSC-governed program is observed in hematopoietic stem cells shifting from an actively proliferating to a quiescent state. TIS cells presented with high expression levels of reprogramming factors (Klf4 and Sox2), which have the potential to initiate ESCL program, and exhibited up-regulation of several transcripts associated with invasive neoplastic features, like Twist1/2, Snai1/2, Cdh2 or Mmp2These findings suggest that senescent cells retain or even increase their initial malignant capacity by promoting a latent stemness program that is kept in check by cellular senescence. Indeed, upon inactivation of the senescence barrier, cells resumed cycling, and showed an increased clonogenic potential compared to matching proliferating lymphoma cells that had not encountered senescence. The relevance of these genetic changes for tumor progression in vivo is currently under investigation.</jats:p> <jats:p>These results suggest a more complex relation between senescence and stemness than intuitively expected. The intended execution of the senescence response evokes critical changes in other fundamental, cancer-related cellular programs, opening the possibility of arresting neoplastic cells on one side, but simultaneously promoting aggressive cancer features, like self-renewal, invasion and motility that may become harmful upon disruption of the “senescence shield”. This calls for a thorough functional reassessment of the senescent phenotype, before employing senescence as a therapeutic option.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec> Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics. Blood
doi_str_mv	10.1182/blood.v116.21.2836.2836
facet_avail	Online Free
finc_class_facet	Biologie Medizin Chemie und Pharmazie
format	ElectronicArticle
fullrecord	blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE2LjIxLjI4MzYuMjgzNg
id	ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE2LjIxLjI4MzYuMjgzNg
institution	DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1
imprint	American Society of Hematology, 2010
imprint_str_mv	American Society of Hematology, 2010
issn	0006-4971 1528-0020
issn_str_mv	0006-4971 1528-0020
language	English
mega_collection	American Society of Hematology (CrossRef)
match_str	milanovic2010therapysenescentlymphomacellsbearpotentiallydetrimentalstemcellcharacteristics
publishDateSort	2010
publisher	American Society of Hematology
recordtype	ai
record_format	ai
series	Blood
source_id	49
title	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
title_unstemmed	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
title_full	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
title_fullStr	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
title_full_unstemmed	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
title_short	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
title_sort	therapy-senescent lymphoma cells bear potentially detrimental stem-cell characteristics.
topic	Cell Biology Hematology Immunology Biochemistry
url	http://dx.doi.org/10.1182/blood.v116.21.2836.2836
publishDate	2010
physical	2836-2836
description	<jats:title>Abstract</jats:title> <jats:p>Abstract 2836</jats:p> <jats:p>Premature senescence is a stress-inducible terminal cell-cycle arrest, which, like apoptosis, prevents propagation of aberrantly proliferating cells. DNA-damaging chemotherapy induces cellular senescence, particularly in cells where apoptosis is no longer available (e.g. due to Bcl2 over-expression). Since senescent cells remain vital, it is critical to understand their long-term fate and ultimate impact on outcome. Given the potential reversibility of senescence by additional genetic events, assessment of a senescence-associated tumorigenic capability appears to be crucial for the development of safe pro-senescent treatment regimens. Since “stemness” is a property that – either confined to a putative cancer stem cell population or endowed in all neoplastic cells – enables malignant transformation and propagation, we decided to investigate features of stemness in senescent Eμ-myc-transgenic B-cell lymphomas.</jats:p> <jats:p>Here, we compared expression changes of stem-cell related gene sets in proliferating vs. treatment-induced senescent (TIS) Eμ-myc lymphoma cells. The clonogenicity and proliferation capacity were assessed in cells released from TIS by acute inactivation of downstream senescence gatekeeper proteins, such as Suv39h1, Klf4 or p53.</jats:p> <jats:p>Our data show that embryonic stem cell-like (ESCL) gene expression signatures, associated with aggressive tumor behavior decrease with TIS induction in Eμ-myc lymphoma cells. However, the adult tissue stem cell (ATSC) gene signature is highly up-regulated, providing the senescent lymphoma cells with an alternative stemness-maintaining prospective. Similar conversion from an ESCL- to an ATSC-governed program is observed in hematopoietic stem cells shifting from an actively proliferating to a quiescent state. TIS cells presented with high expression levels of reprogramming factors (Klf4 and Sox2), which have the potential to initiate ESCL program, and exhibited up-regulation of several transcripts associated with invasive neoplastic features, like Twist1/2, Snai1/2, Cdh2 or Mmp2These findings suggest that senescent cells retain or even increase their initial malignant capacity by promoting a latent stemness program that is kept in check by cellular senescence. Indeed, upon inactivation of the senescence barrier, cells resumed cycling, and showed an increased clonogenic potential compared to matching proliferating lymphoma cells that had not encountered senescence. The relevance of these genetic changes for tumor progression in vivo is currently under investigation.</jats:p> <jats:p>These results suggest a more complex relation between senescence and stemness than intuitively expected. The intended execution of the senescence response evokes critical changes in other fundamental, cancer-related cellular programs, opening the possibility of arresting neoplastic cells on one side, but simultaneously promoting aggressive cancer features, like self-renewal, invasion and motility that may become harmful upon disruption of the “senescence shield”. This calls for a thorough functional reassessment of the senescent phenotype, before employing senescence as a therapeutic option.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec>
container_issue	21
container_start_page	2836
container_title	Blood
container_volume	116
format_de105	Article, E-Article
format_de14	Article, E-Article
format_de15	Article, E-Article
format_de520	Article, E-Article
format_de540	Article, E-Article
format_dech1	Article, E-Article
format_ded117	Article, E-Article
format_degla1	E-Article
format_del152	Buch
format_del189	Article, E-Article
format_dezi4	Article
format_dezwi2	Article, E-Article
format_finc	Article, E-Article
format_nrw	Article, E-Article
_version_	1792326963217563656
geogr_code	not assigned
last_indexed	2024-03-01T12:29:04.322Z
geogr_code_person	not assigned
openURL	url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Therapy-Senescent+Lymphoma+Cells+Bear+Potentially+Detrimental+Stem-Cell+Characteristics.&rft.date=2010-11-19&genre=article&issn=1528-0020&volume=116&issue=21&spage=2836&epage=2836&pages=2836-2836&jtitle=Blood&atitle=Therapy-Senescent+Lymphoma+Cells+Bear+Potentially+Detrimental+Stem-Cell+Characteristics.&aulast=Schmitt&aufirst=Clemens&rft_id=info%3Adoi%2F10.1182%2Fblood.v116.21.2836.2836&rft.language%5B0%5D=eng
SOLR
_version_	1792326963217563656
author	Milanovic, Maja, Dörr, Jan, Lenze, Dido, Hummel, Michael, Dörken, Bernd, Schmitt, Clemens
author_facet	Milanovic, Maja, Dörr, Jan, Lenze, Dido, Hummel, Michael, Dörken, Bernd, Schmitt, Clemens, Milanovic, Maja, Dörr, Jan, Lenze, Dido, Hummel, Michael, Dörken, Bernd, Schmitt, Clemens
author_sort	milanovic, maja
container_issue	21
container_start_page	2836
container_title	Blood
container_volume	116
description	<jats:title>Abstract</jats:title> <jats:p>Abstract 2836</jats:p> <jats:p>Premature senescence is a stress-inducible terminal cell-cycle arrest, which, like apoptosis, prevents propagation of aberrantly proliferating cells. DNA-damaging chemotherapy induces cellular senescence, particularly in cells where apoptosis is no longer available (e.g. due to Bcl2 over-expression). Since senescent cells remain vital, it is critical to understand their long-term fate and ultimate impact on outcome. Given the potential reversibility of senescence by additional genetic events, assessment of a senescence-associated tumorigenic capability appears to be crucial for the development of safe pro-senescent treatment regimens. Since “stemness” is a property that – either confined to a putative cancer stem cell population or endowed in all neoplastic cells – enables malignant transformation and propagation, we decided to investigate features of stemness in senescent Eμ-myc-transgenic B-cell lymphomas.</jats:p> <jats:p>Here, we compared expression changes of stem-cell related gene sets in proliferating vs. treatment-induced senescent (TIS) Eμ-myc lymphoma cells. The clonogenicity and proliferation capacity were assessed in cells released from TIS by acute inactivation of downstream senescence gatekeeper proteins, such as Suv39h1, Klf4 or p53.</jats:p> <jats:p>Our data show that embryonic stem cell-like (ESCL) gene expression signatures, associated with aggressive tumor behavior decrease with TIS induction in Eμ-myc lymphoma cells. However, the adult tissue stem cell (ATSC) gene signature is highly up-regulated, providing the senescent lymphoma cells with an alternative stemness-maintaining prospective. Similar conversion from an ESCL- to an ATSC-governed program is observed in hematopoietic stem cells shifting from an actively proliferating to a quiescent state. TIS cells presented with high expression levels of reprogramming factors (Klf4 and Sox2), which have the potential to initiate ESCL program, and exhibited up-regulation of several transcripts associated with invasive neoplastic features, like Twist1/2, Snai1/2, Cdh2 or Mmp2These findings suggest that senescent cells retain or even increase their initial malignant capacity by promoting a latent stemness program that is kept in check by cellular senescence. Indeed, upon inactivation of the senescence barrier, cells resumed cycling, and showed an increased clonogenic potential compared to matching proliferating lymphoma cells that had not encountered senescence. The relevance of these genetic changes for tumor progression in vivo is currently under investigation.</jats:p> <jats:p>These results suggest a more complex relation between senescence and stemness than intuitively expected. The intended execution of the senescence response evokes critical changes in other fundamental, cancer-related cellular programs, opening the possibility of arresting neoplastic cells on one side, but simultaneously promoting aggressive cancer features, like self-renewal, invasion and motility that may become harmful upon disruption of the “senescence shield”. This calls for a thorough functional reassessment of the senescent phenotype, before employing senescence as a therapeutic option.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec>
doi_str_mv	10.1182/blood.v116.21.2836.2836
facet_avail	Online, Free
finc_class_facet	Biologie, Medizin, Chemie und Pharmazie
format	ElectronicArticle
format_de105	Article, E-Article
format_de14	Article, E-Article
format_de15	Article, E-Article
format_de520	Article, E-Article
format_de540	Article, E-Article
format_dech1	Article, E-Article
format_ded117	Article, E-Article
format_degla1	E-Article
format_del152	Buch
format_del189	Article, E-Article
format_dezi4	Article
format_dezwi2	Article, E-Article
format_finc	Article, E-Article
format_nrw	Article, E-Article
geogr_code	not assigned
geogr_code_person	not assigned
id	ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE2LjIxLjI4MzYuMjgzNg
imprint	American Society of Hematology, 2010
imprint_str_mv	American Society of Hematology, 2010
institution	DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1
issn	0006-4971, 1528-0020
issn_str_mv	0006-4971, 1528-0020
language	English
last_indexed	2024-03-01T12:29:04.322Z
match_str	milanovic2010therapysenescentlymphomacellsbearpotentiallydetrimentalstemcellcharacteristics
mega_collection	American Society of Hematology (CrossRef)
physical	2836-2836
publishDate	2010
publishDateSort	2010
publisher	American Society of Hematology
record_format	ai
recordtype	ai
series	Blood
source_id	49
spelling	Milanovic, Maja Dörr, Jan Lenze, Dido Hummel, Michael Dörken, Bernd Schmitt, Clemens 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v116.21.2836.2836 <jats:title>Abstract</jats:title> <jats:p>Abstract 2836</jats:p> <jats:p>Premature senescence is a stress-inducible terminal cell-cycle arrest, which, like apoptosis, prevents propagation of aberrantly proliferating cells. DNA-damaging chemotherapy induces cellular senescence, particularly in cells where apoptosis is no longer available (e.g. due to Bcl2 over-expression). Since senescent cells remain vital, it is critical to understand their long-term fate and ultimate impact on outcome. Given the potential reversibility of senescence by additional genetic events, assessment of a senescence-associated tumorigenic capability appears to be crucial for the development of safe pro-senescent treatment regimens. Since “stemness” is a property that – either confined to a putative cancer stem cell population or endowed in all neoplastic cells – enables malignant transformation and propagation, we decided to investigate features of stemness in senescent Eμ-myc-transgenic B-cell lymphomas.</jats:p> <jats:p>Here, we compared expression changes of stem-cell related gene sets in proliferating vs. treatment-induced senescent (TIS) Eμ-myc lymphoma cells. The clonogenicity and proliferation capacity were assessed in cells released from TIS by acute inactivation of downstream senescence gatekeeper proteins, such as Suv39h1, Klf4 or p53.</jats:p> <jats:p>Our data show that embryonic stem cell-like (ESCL) gene expression signatures, associated with aggressive tumor behavior decrease with TIS induction in Eμ-myc lymphoma cells. However, the adult tissue stem cell (ATSC) gene signature is highly up-regulated, providing the senescent lymphoma cells with an alternative stemness-maintaining prospective. Similar conversion from an ESCL- to an ATSC-governed program is observed in hematopoietic stem cells shifting from an actively proliferating to a quiescent state. TIS cells presented with high expression levels of reprogramming factors (Klf4 and Sox2), which have the potential to initiate ESCL program, and exhibited up-regulation of several transcripts associated with invasive neoplastic features, like Twist1/2, Snai1/2, Cdh2 or Mmp2These findings suggest that senescent cells retain or even increase their initial malignant capacity by promoting a latent stemness program that is kept in check by cellular senescence. Indeed, upon inactivation of the senescence barrier, cells resumed cycling, and showed an increased clonogenic potential compared to matching proliferating lymphoma cells that had not encountered senescence. The relevance of these genetic changes for tumor progression in vivo is currently under investigation.</jats:p> <jats:p>These results suggest a more complex relation between senescence and stemness than intuitively expected. The intended execution of the senescence response evokes critical changes in other fundamental, cancer-related cellular programs, opening the possibility of arresting neoplastic cells on one side, but simultaneously promoting aggressive cancer features, like self-renewal, invasion and motility that may become harmful upon disruption of the “senescence shield”. This calls for a thorough functional reassessment of the senescent phenotype, before employing senescence as a therapeutic option.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec> Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics. Blood
spellingShingle	Milanovic, Maja, Dörr, Jan, Lenze, Dido, Hummel, Michael, Dörken, Bernd, Schmitt, Clemens, Blood, Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics., Cell Biology, Hematology, Immunology, Biochemistry
title	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
title_full	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
title_fullStr	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
title_full_unstemmed	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
title_short	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
title_sort	therapy-senescent lymphoma cells bear potentially detrimental stem-cell characteristics.
title_unstemmed	Therapy-Senescent Lymphoma Cells Bear Potentially Detrimental Stem-Cell Characteristics.
topic	Cell Biology, Hematology, Immunology, Biochemistry
url	http://dx.doi.org/10.1182/blood.v116.21.2836.2836